Page 1113 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 61 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults 980.e3

77. de Witte T, Brand R, van Biezen A, et al: Allogeneic stem cell trans- 93. Koreth J, Pidala J, Perez WS, et al: Role of reduced-intensity condition-
plantation for patients with refractory anaemia with matched related ing allogeneic hematopoietic stem-cell transplantation in older patients
and unrelated donors: delay of the transplant is associated with inferior with de novo myelodysplastic syndromes: an international collaborative
survival. Br J Haematol 146:627, 2009. decision analysis. J Clin Oncol 31:2662, 2013.
78. Atallah E, Abrams J, Ayash L, et al: Long term follow-up of allogeneic 94. Alessandrino EP, Porta MG, Malcovati L, et al: Optimal timing of
stem cell transplantation in patients with myelodysplastic syndromes allogeneic hematopoietic stem cell transplantation in patients with
using busulfan, cytosine arabinoside, and cyclophosphamide. Am J myelodysplastic syndrome. Am J Hematol 88:581, 2013.
Hematol 85:579, 2010. 95. Della Porta M, Alessandrino E, Jackson C, et al: Decision analysis of
79. Jurado M, Deeg HJ, Storer B, et al: Hematopoietic stem cell transplan- allogeneic stem cell transplantation in patients with myelodysplastic
tation for advanced myelodysplastic syndrome after conditioning with syndrome stratified according to the revised international prognostic
busulfan and fractionated total body irradiation is associated with low scoring system (IPSS-R). Blood 124:531, 2014.
relapse rate but considerable nonrelapse mortality. Biol Blood Marrow 96. Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life
Transplant 8:161, 2002. expectancy in myelodysplastic syndromes classified according to who
80. Nakamura R, Rodriguez R, Palmer J, et al: Reduced-intensity con- criteria: a basis for clinical decision making. J Clin Oncol 23:7594,
ditioning for allogeneic hematopoietic stem cell transplantation with 2005.
fludarabine and melphalan is associated with durable disease control 97. Alessandrino EP, Della Porta MG, Bacigalupo A, et al: WHO classifica-
in myelodysplastic syndrome. Bone Marrow Transplant 40:843, tion and WPSS predict posttransplantation outcome in patients with
2007. myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto
81. de Lima M, Couriel D, Thall PF, et al: Once-daily intravenous busulfan di Midollo Osseo (GITMO). Blood 112:895, 2008.
and fludarabine: clinical and pharmacokinetic results of a myeloabla- 98. Bejar R, Levine R, Ebert BL: Unraveling the molecular pathophysiology
tive, reduced-toxicity conditioning regimen for allogeneic stem cell of myelodysplastic syndromes. J Clin Oncol 29:504, 2011.
transplantation in AML and MDS. Blood 104:857, 2004. 99. Bejar R, Stevenson KE, Caughey B, et al: Somatic mutations predict
82. Alatrash G, de Lima M, Hamerschlak N, et al: Myeloablative reduced- poor outcome in patients with myelodysplastic syndrome after hema-
toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell topoietic stem-cell transplantation. J Clin Oncol 32:2691, 2014.
transplant for patients with acute myeloid leukemia or myelodysplastic 100. Della Porta MG, Malcovati L: Clinical relevance of extra-hematologic
syndrome in the sixth through eighth decades of life. Biol Blood Marrow comorbidity in the management of patients with myelodysplastic
Transplant 17:1490, 2011. syndrome. Haematologica 94:602, 2009.
83. Valcarcel D, Martino R, Caballero D, et al: Sustained remissions of 101. McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on
high-risk acute myeloid leukemia and myelodysplastic syndrome after outcome of reduced-intensity hematopoietic cell transplantation
reduced-intensity conditioning allogeneic hematopoietic transplanta- for older patients with acute myeloid leukemia in first complete
tion: chronic graft-versus-host disease is the strongest factor improving remission or with myelodysplastic syndrome. J Clin Oncol 28:1878,
survival. J Clin Oncol 26:577, 2008. 2010.
84. Cho BS, Kim YJ, Cho SG, et al: The beneficial effect of chronic 102. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplanta-
graft-versus-host disease on the clinical outcome of transplantation tion (HCT)-specific comorbidity index: a new tool for risk assessment
with fludarabine/busulfan-based reduced-intensity conditioning for before allogeneic HCT. Blood 106:2912, 2005.
patients with de novo myelodysplastic syndrome. Int J Hematol 85:446, 103. Sorror ML, Sandmaier BM, Storer BE, et al: Comorbidity and disease
2007. status based risk stratification of outcomes among patients with acute
85. Kroger N, Bornhauser M, Ehninger G, et al: Allogeneic stem cell myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic
transplantation after a fludarabine/busulfan-based reduced-intensity cell transplantation. J Clin Oncol 25:4246, 2007.
conditioning in patients with myelodysplastic syndrome or secondary 104. Zipperer E, Pelz D, Nachtkamp K, et al: The hematopoietic stem
acute myeloid leukemia. Ann Hematol 82:336, 2003. cell transplantation comorbidity index is of prognostic relevance
86. Martino R, Valcarcel D, Brunet S, et al: Comparable non-relapse mor- for patients with myelodysplastic syndrome. Haematologica 94:729,
tality and survival after hla-identical sibling blood stem cell transplanta- 2009.
tion with reduced or conventional-intensity preparative regimens for 105. Sorror ML, Storb RF, Sandmaier BM, et al: Comorbidity-age index:
high-risk myelodysplasia or acute myeloid leukemia in first remission. a clinical measure of biologic age before allogeneic hematopoietic cell
Bone Marrow Transplant 41:33, 2008. transplantation. J Clin Oncol 32:3249, 2014.
87. Lim Z, Brand R, Martino R, et al: Allogeneic hematopoietic stem-cell 106. Pullarkat V, Blanchard S, Tegtmeier B, et al: Iron overload adversely
transplantation for patients 50 years or older with myelodysplastic affects outcome of allogeneic hematopoietic cell transplantation. Bone
syndromes or secondary acute myeloid leukemia. J Clin Oncol 28:405, Marrow Transplant 42:799, 2008.
2010. 107. Warlick ED, Cioc A, Defor T, et al: Allogeneic stem cell transplantation
88. Kröger N, Brand R, Niederwieser D, et al: Reduced intensity vs. for adults with myelodysplastic syndromes: importance of pretransplant
Standard conditioning followed by allogeneic stem cell transplantation disease burden. Biol Blood Marrow Transplant 15:30, 2009.
for patients with MDS or secondary AML: a prospective, randomized 108. Nakai K, Kanda Y, Fukuhara S, et al: Value of chemotherapy before
phase iii study of the chronic malignancies working party of the EBMT allogeneic hematopoietic stem cell transplantation from an HLA-
(RICMAC-trial). Blood 124:320, 2014. identical sibling donor for myelodysplastic syndrome. Leukemia 19:396,
89. Nachtkamp K, Kundgen A, Strupp C, et al: Impact on survival of 2005.
different treatments for myelodysplastic syndromes (MDS). Leuk Res 109. Field T, Perkins J, Huang Y, et al: 5-Azacitidine for myelodysplasia
33:1024, 2009. before allogeneic hematopoietic cell transplantation. Bone Marrow
90. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic Transplant 45:255, 2010.
bone marrow transplantation for the myelodysplastic syndromes: 110. Gerds AT, Gooley TA, Estey EH, et al: Pretransplantation therapy
delayed transplantation for low-risk myelodysplasia is associated with with azacitidine vs induction chemotherapy and posttransplantation
improved outcome. Blood 104:579, 2004. outcome in patients with MDS. Biol Blood Marrow Transplant 18:1211,
91. Lee JH, Lee JH, Lim SN, et al: Allogeneic hematopoietic cell trans- 2012.
plantation for myelodysplastic syndrome: prognostic significance of 111. Damaj G, Duhamel A, Robin M, et al: Impact of azacitidine before
pre-transplant IPSS score and comorbidity. Bone Marrow Transplant allogeneic stem-cell transplantation for myelodysplastic syndromes: a
45:450, 2010. study by the Societe Francaise de Greffe de Moelle et de Therapie-
92. Della Porta MG, Alessandrino EP, Bacigalupo A, et al: Predictive Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin
factors for the outcome of allogeneic transplantation in patients with Oncol 30:4533, 2012.
MDS stratified according to the revised IPSS-R. Blood 123:2333, 112. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, et al: The DNA
2014. demethylating agent 5-aza-2’-deoxycytidine induces expression of